Semax side effects by evidence tier: what the Russian registration label and clinical series describe, what rodent work adds, the uncontrolled reports, and the gaps a Western trial would fill.
Semax — the ACTH(4-7) analogue Met-Glu-His-Phe-Pro-Gly-Pro — is unusual among research peptides in having a prescription label. It has been registered in Russia as a nasal solution since the 1990s, which means it carries a list of contraindications and a body of clinical use that most compounds on this site lack. It also means the tolerability record is written in Russian, from small and mostly open studies, and has never been examined by a regulator outside that market. This page reports what that record describes, tier by tier. It is a research reference beside the Semax profile, not advice.
Semax is registered in Russia in two strengths: a 0.1 percent nasal solution for cognitive and asthenic indications, and a 1 percent solution used in acute ischaemic stroke. The label lists few contraindications — hypersensitivity, pregnancy and acute psychotic states — and the registration rests on Russian clinical series in stroke, chronic cerebrovascular insufficiency and attention, most of them small and rarely placebo-controlled. None was published in a major Western journal and none is registered on ClinicalTrials.gov.
A registration is meaningful evidence of one thing: that years of clinical use in a formulated intranasal product did not generate a safety signal large enough to withdraw it. It is not evidence about incidence of common effects, because the trials had no placebo arm to subtract background symptoms from; it is not evidence about rare events, because the cohorts were small; and it applies to a sterile, formulated nasal solution at labelled amounts, not to lyophilised bulk peptide reconstituted in a laboratory. The Semax research overview sets out what the Russian literature claims about efficacy; the Semax dosage notes describe how each study administered it.
The earliest English-language human study, published in Neuroscience Research Communications in 1996, gave intranasal Semax to healthy volunteers and reported nootropic-like effects on attention and short-term memory without adverse effects. The larger Russian series in acute stroke and vascular cognitive impairment reported no serious adverse events attributable to the peptide.
One finding in that record is mechanistically specific. Semax is built from ACTH residues 4 to 7, which lack the residues that activate the adrenal melanocortin receptor, so it does not raise cortisol the way full-length ACTH does; rodent studies confirmed the absence of that hormonal effect. Whatever Semax does, the adrenal side effects of ACTH itself — fluid retention, glucose and blood-pressure changes — are not part of its pharmacology on the available evidence.
The mechanism studies are the deepest part of the literature and they were not designed to measure tolerability. A 2006 study in Brain Research found that a single 50 µg/kg intranasal dose raised BDNF and TrkB expression in the rat hippocampus within hours; a 2005 study in Neurochemical Research reported activation of dopaminergic and serotonergic systems; and transcriptomic work in a rat stroke model, published in Molecular Genetics and Genomics in 2014, reported shifts in the expression of hundreds of genes, including immune-response genes. Doses across the rodent literature ran from roughly 0.05 to 0.6 mg/kg, intranasally or intraperitoneally, without reported toxicity.
What animal work of this kind cannot say is whether a compound that changes neurotrophic, monoaminergic and transcriptional signalling has effects on mood, behaviour or seizure threshold in people. Those are the theoretical concerns, and they are theoretical in both directions: neither demonstrated nor ruled out.
Research-community reports describe nasal irritation or a burning sensation with intranasal solutions, transient headache, and irritability or restlessness at higher amounts, occasionally with disturbed sleep when used late in the day. None comes from a controlled study. They have no denominator, no blinding and no verification of what the solution contained, so they cannot establish incidence or causation. They are hypotheses that a controlled trial would test.
There is no double-blind, placebo-controlled trial of Semax in the English-language literature and no long-term follow-up published in English. There is no data on interactions with medicines, which matters because a compound reported to act on dopaminergic and serotonergic systems could in principle interact with stimulants and antidepressants, and one that inhibits enkephalin-degrading enzymes could affect opioid signalling. None of this has been studied.
Two other gaps are specific to the research market. N-acetyl Semax, sometimes also C-terminally amidated, is a different molecule, and the Russian clinical data does not apply to it. And the pairing with Selank — the reason the Semax + Selank 10 mg blend exists — has never been examined in a published study; the Semax vs Selank comparison covers what is and is not known about the difference.
Semax's N-terminal methionine oxidises to methionine sulfoxide, which appears as a distinct HPLC peak and is the main chemical degradation route. A solution stored warm, repeatedly opened or reconstituted for a spray device with a large air headspace will carry more of it. A share of the irritation and headache reported in unregulated use plausibly traces to that, to synthesis impurities, or to endotoxin, rather than to the peptide. Reading the certificate of analysis for purity and oxidation products is the only way to separate compound effects from product effects — see lab testing and COAs and the cold-chain and shelf-life guide. The Semax 5 mg vial sold here is third-party HPLC tested by lot.
Semax has no Health Canada market authorisation and no Drug Identification Number; its Russian registration has no standing under Canadian law, and research-grade material is sold in Canada for laboratory use only. The U.S. FDA has not reviewed Semax under its section 503A bulk-substance process, so it is unreviewed there rather than cleared or restricted. Semax is not named on the WADA Prohibited List, though the list's open categories are broad enough that tested athletes should verify with their federation.
Does Semax have a documented side-effect profile? Partly. As a registered Russian nasal solution it has a label listing hypersensitivity, pregnancy and acute psychotic states as contraindications, and Russian clinical series reported no serious adverse events. There is no placebo-controlled adverse-event data and nothing collected to Western standards.
Does Semax raise cortisol like ACTH? No on the available evidence. The ACTH(4-7) fragment lacks the residues that activate the adrenal melanocortin receptor, and rodent studies confirmed the absence of a cortisol response.
What side effects do uncontrolled reports describe? Nasal irritation with intranasal solutions, transient headache, and irritability or restlessness at higher amounts. These are self-reports without a denominator or a comparator.
Does the Russian safety data apply to research-grade Semax? No. The registration covers a sterile, formulated nasal solution at labelled amounts. Bulk lyophilised peptide, reconstituted in a laboratory, is a different product with its own purity and stability questions.
Is there safety data on the Semax + Selank combination? No published study has examined the two together. Each has a Russian tolerability record on its own; the combination is untested.
Is this medical advice? No. This page summarises published research for laboratory reference. It is not medical advice, not a safety assurance, and not a dosing recommendation. Semax is sold here for research use only.
